Biotechnology News and Research

RSS

BioMed declares $0.20 first quarter dividend

BioMed Realty Trust, Inc. today announced that its board of directors has declared a first quarter 2011 dividend of $0.20 per share of common stock, representing a 17.6% increase over the company's fourth quarter 2010 dividend of $0.17 per share. The dividend is equivalent to an annualized dividend of $0.80 per common share.

14 Mar 2011

HemaCare reports $7.0 million revenue for fourth quarter 2010

HemaCare Corporation announced today that the Company generated fourth quarter revenue of $7.0 million and a net loss of $197,000, or $0.02/share, compared to fourth quarter 2009 revenue of $8.2 million and net income of $195,000, or $0.02/share.

14 Mar 2011

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.

14 Mar 2011

Life Technologies receives FDA 510(k) clearance for StemPro MSC SFM device

Life Technologies Corporation today announced it has received FDA 510(k) clearance for StemPro MSC SFM – a first for this next-generation stem cell culture medium that is now cleared as a medical device and satisfies a crucial requirement for researchers involved in clinical trials in the United States.

14 Mar 2011

CTI, Chroma enter agreement to co-develop and license tosedostat

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced today that the companies have entered into a co-development and license agreement providing CTI with exclusive marketing and co-development rights to Chroma's drug candidate tosedostat in North, Central and South America.

14 Mar 2011

US District Court rules in favor of Watson in FENTORA patent litigation

On March 11, 2011, the United States District Court for the District of Delaware issued a decision as to a portion of the patent litigation brought by Cephalon Inc., and its wholly-owned subsidiary CIMA Labs, Inc., against Watson Pharmaceuticals, Inc., and its wholly-owned subsidiary Watson Laboratories, Inc., pertaining to Cephalon's FENTORA® fentanyl buccal tablet product.

14 Mar 2011

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.

11 Mar 2011

NIH awards InDevR $3 million Phase II SBIR grant for influenza-related research

InDevR announced today that it has been awarded a Phase II Small Business Innovation Research grant from the National Institutes of Health in the amount of $3 million over the next 3 years.

11 Mar 2011

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Ardea Biosciences, Inc., a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and announced fourth quarter and full-year 2010 financial results.

11 Mar 2011

Verenium repurchases $28.4 million in outstanding convertible notes

Verenium Corporation, a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it repurchased $28.4 million in principal amount of its outstanding convertible notes in a series of privately-negotiated transactions.

11 Mar 2011

Bill Gates and Schrödinger co-founder invest in Nimbus to advance large B-cell lymphoma programs

Nimbus Discovery LLC, a biopharmaceutical company using state-of the-art computational technology to discover novel medicines against exciting but difficult-to-drug disease targets, today announced an extension of its seed round with an investment by Bill Gates and Dr. Richard Friesner, the co-founder of Schrödinger and Professor of Chemistry at Columbia University. Atlas Venture, the founding investor, also participated.

11 Mar 2011

CIC to host Scientific Colloquium on tumor immunotherapy in National Harbor, MD

The Cancer Immunotherapy Consortium, a program of the nonprofit Cancer Research Institute, will host its 2011 Scientific Colloquium March 17-19, 2011, at the Gaylord National Hotel and Convention Center in National Harbor, MD.

11 Mar 2011

Simcere files IND with SFDA of China for APX003 to treat cancer

Apexigen, Inc., an emerging biopharmaceutical company focusing on the development of monoclonal antibody therapeutics, announced today that its partner, Simcere Pharmaceutical Group, a leading pharmaceutical company in China, filed an Investigational New Drug application with the State Food and Drug Administration of China to evaluate APX003 as a potential cancer therapy.

11 Mar 2011

FDA holds Senesco's SNS01-T clinical study due to delay of supplier's DMF updation

Senesco Technologies, Inc., announced today that the U.S. Food and Drug Administration has informed the Company that its planned study in multiple myeloma is on hold until the Drug Master File of one of its suppliers is updated.

11 Mar 2011

ACT's hESC-derived RPE cells receive EMA positive opinion for Orphan Drug Designation for Stargardt's disease

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has announced a positive opinion of ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells for designation as an orphan medicinal product for the treatment of Stargardt's disease.

11 Mar 2011

Genentech announces positive outcomes from Lucentis Phase III trial against DME

Genentech, a member of the Roche Group, today announced that two-year results from a pivotal Phase III trial showed patients with diabetic macular edema who received Lucentis experienced rapid and sustained improvement in vision compared to those who received a placebo injection.

11 Mar 2011

Jasco initiates pancreatic cancer research program with NCCU in Durham

Jasco Pharmaceuticals, LLC has initiated a collaborative research program with North Carolina Central University in Durham, North Carolina, focused on developing therapeutics for pancreatic cancer that function through a Pim kinase mechanism of action.

11 Mar 2011

Cardiome total revenue for fiscal 2010 is $66.1 million

Cardiome Pharma Corp. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

10 Mar 2011